Clinical Trial

A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
An Exploratory, Single-Arm, Open-Label, Dose-Escalation Study of the Safety, Tolerability, PK, PD, and Efficacy of Anti-CD19/BCMA Universal CAR-T Therapy RD06-05 in Autoimmune Diseases (including SLE/LN, AAV/AAGN, Anti-GBM, MN, SSc, and IIM).
Protocol Amendment History 1 change
notable Enrollment increased: 84 -> 96 participants 2026-08-04
Trial Details
NCT Number NCT07203404
Lead Sponsor Nanjing Bioheng Biotech Co., Ltd.
Conditions SLE, LN, ANCA Associated Vasculitis, ANCA-Associated Glomerulonephritis, Anti-GBM Disease, MN, SSc, IIM +1 more
Enrollment 96 participants
Start Date 2025-07-24
Primary Completion 2027-07-23 (estimated)
Study Completion 2028-07-23 (estimated)
Updated on ClinicalTrials.gov 2026-08-03